跳至主要内容
临床试验/ACTRN12624000669594
ACTRN12624000669594尚未招募Unknown

Evaluate the use of Early-Stage Follicular Lymphoma International ImmunoTherapy Registry and initial analysis plan to describe progression-free survival for patients with stage I-II follicular lymphoma treated with radiotherapy alone compared with radiotherapy plus immunotherapy.

Peter MacCallum Cancer Centre0 个研究点目标入组 300 人开始时间: 2024年5月27日最近更新:

试验速览

阶段
Unknown
状态
尚未招募
发起方
入组人数
300

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

年龄范围
18 Years 至 o limit(—)
性别
All

入选标准

  • 1. Male or female, > 18 years of age.
  • 2. Patients with histologically WHO grade 1, 2 or 3a FL.
  • 3. Treated with curative intent RT to any dose
  • 4. Intended to receive either no further treatment or adjuvant treatment containing anti-CD20 antibody therapy or other immunotherapy
  • 5. Minimum follow up of 3 months from commencement of treatment.

排除标准

  • 1. Previous treatment for FL
  • 2. Composite lymphoma
  • 3. Previous diagnosis of lymphoma
  • 4. Treated with wide-field RT (RT involving both sides of the diaphragm targeting uninvolved nodal sites)

研究者

发起方
Peter MacCallum Cancer Centre

相似试验